| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 422.26 Cr | 31.8% | 23.1% |
| Total Income | 434.51 Cr | 29.6% | 22.9% |
| Expenditure | 477.38 Cr | 17.8% | 3.1% |
| PBT | -42.87 Cr | 315.3% | 168.3% |
| Net Profit | -45.19 Cr | 643.8% | 197.4% |
| OPM | 0.27% | 13.00pp | 18.65pp |
| NPM | -10.40% | 11.75pp | 18.63pp |
| EPS | 0.63 | 23.5% | 50.8% |
Guided low, delivered loss. Recovery path unclear.
Revenue miss was flagged as a trough; profit collapse was not. A consolidation-heavy EBITDA drag obscures a healthier standalone business and muddies the H2 recovery thesis.
₹4,223 Cr
-23.1% YoY (as guided)
-₹45.2 Cr
-197.4% YoY (profit collapse)
9.2%
₹3,599 Cr revenue
2.2%
NJ Bio drag -₹328 Cr
Cohance flagged Q1 FY27 as a trough — revenue down 23%, EBITDA minimal — and delivered exactly that. What management did not fully preview: profit would crater 197% and turn negative. The culprit is not revenue collapse, but NJ Bio consolidation. The acquired ADC payload subsidiary contributed ₹350 crore in revenue but -₹328 crore in EBITDA — a 94% negative margin that pulled the consolidated P&L underwater, even as the standalone business (₹3,599 crore revenue at 9.2% EBITDA margin) remained operationally sound.
The standalone-consolidated gap
Segment reality is split. Sapala (oligonucleotides) delivered ₹274 crore at 2.5x YoY growth with strong EBITDA margins — the only bright spot, with orphan drug program shipments live and amidites facility commercialization underway. Pharma CDMO (small molecule, ADC linkers, KSM) revenue fell 38.7% YoY, but this is shipment timing: 10 Phase 3 molecules are in the pipeline, with deliveries moving from Q1 into Q2/Q3. Specialty Chemicals declined 34.7% YoY, with AgChem weak but FY27 positioned as 'year of qualification' for new products. API+ held up (60% of standalone revenue), with favorable pricing and product mix offsetting formulation timing delays. But NJ Bio — the consolidation now mandatory rather than optional — remains the anchor on consolidated margin.
Claims vs. what holds up
Q1 would be the lowest quarter as guided
SupportedRevenue ₹4,223 Cr, down 23.1% YoY, matching prior call forecast
Sapala 2.5x growth in oligonucleotides
SupportedDelivered ₹274 Cr at 2.5x YoY with maintained EBITDA margins
NJ Bio losses temporary, managed for revenue growth
OverstatedNJ Bio -₹328 Cr EBITDA on ₹350 Cr revenue (94% negative margin); biotech FTE customers lost due to funding headwinds
Restocking order secured for destocked molecule
PartialOne molecule order secured but spread over 2 years (Q4 FY27 → FY28); second molecule timing unclear
Pharma CDMO to see strong improvement driven by Phase 3 conversions
Partial10 Phase 3 molecules in pipeline, >50% approval hoped; recent revenue decline 38.7% YoY on shipment timing, not demand destruction
Standalone 9.2% EBITDA margin sustainable
OverstatedStandalone margin 9.2% on revenue base; historically 30%+. Sustainability questionable given CDMO segment down 38.7%
What changed on this call
Three material shifts from prior guidance: (1) NJ Bio consolidation now mandatory. The acquisition integration pulled consolidated EBITDA margin down from 9.2% (standalone) to 2.2%. This was acknowledged but not flagged as a new or material surprise—signaling underestimated integration risk. (2) ₹1 billion FY30 revenue target downgraded to 'aspiration'. CEO Umang Vohra explicitly said the target 'may be a little bit away' over the next 3–4 years and deferred granularity to December. This is a meaningful credibility hit. (3) H2 FY27 recovery thesis reaffirmed but timeline vague. Phase 3 conversions (10 molecules, >50% approval hoped), restocking over 2 years, Sapala scaling—all material but unproven, with no quantified milestone or confidence interval.
Sapala oligonucleotide 2.5x growth with orphan drug program live
Phase 3 CDMO pipeline (10 molecules) positioned for 2–3 year growth
ADC payload differentiation vs. Chinese suppliers gaining traction
Net cash ₹2,512 Cr; strong balance sheet for capex
Commercial OTIF 100%; customer audits pass without critical findings
NJ Bio -₹328 Cr EBITDA loss on ₹350 Cr revenue (94% negative margin) not improving
Biotech funding headwinds caused FTE customer loss; path to profitability unclear
Phase 3 approval >50% is aspiration, not committed; execution risk high
Restocking realization phased over 2 years; limits near-term revenue recovery
Small molecule CDMO segment down 38.7% YoY; differentiation vs. peers unproven
₹1B FY30 target downgraded to aspiration; credibility gap on long-term targets
Margin recovery path and magnitude unquantified; deferred to December
CEO 3–4 months in role; CFO departing 13 Sep 2026; succession risk in near term
Ranked risks: what should concern a holder most
NJ Bio profitability drag unresolved
High₹328 Cr EBITDA loss on ₹350 Cr revenue (94% margin) pulls consolidated P&L. Management acknowledges biotech funding headwinds and FTE customer loss but offers no breakeven timeline. Until NJ Bio scales revenue or cuts cost, consolidated margin cannot normalize.
Phase 3 molecule conversion >50% is aspiration, not guarantee
HighH2 recovery thesis hinges on >50% of 10 Phase 3 molecules getting approval. But clinical failures, regulatory delays, or customer delays (entrenched with 1–2 suppliers already) could push timeline into FY28. No fallback if approval rate <50%.
Restocking realization phased over 2 years, not immediate
MediumPrior destocking impact was ₹260 Cr. One molecule restocking order secured but spread Q4 FY27 → FY28 (2 years). Second molecule timing uncertain. Limits FY27 revenue lift; recovery weighted to FY28+.
Small molecule CDMO segment losing share and differentiation unproven
MediumPharma CDMO (small molecule + ADC linkers + KSM) down 38.7% YoY. Management claims moat is relationships (7–10 years to build), science, niche chemistry. But peers (Divi's, Laurus) are larger and faster. Cohance in catch-up phase; moat unproven.
Margin recovery timeline vague; deferred to December
MediumStandalone margin 9.2% vs. 30%+ historical; consolidated 2.2%. Management says margins will 'recover' by end FY27 and 'accelerate FY28' but offers no magnitude or detailed path. Lack of specificity increases execution risk.
How the street is reading this
The market believed the recovery narrative. The day-1 pop of +3.49% after the result announcement (Aug 5) held and strengthened: by day 3 it was +5.2%, and by day 5 it had settled at +4.59%, a managed hold. No fade suggests institutional conviction in the H2 thesis. However, context matters: the stock trades at ₹440.65, down 50.65% from its all-time high of ₹892.85, and sits above its 20-day SMA (₹435.68) but below its 200-day (₹448.29) — a position that signals near-term relief but longer-term weakness. FII ownership ticked up 0.91 percentage points to 6.50%, a modest add into weakness, while DII trimmed 1.7 points to 20.09%, suggesting domestic institutions are more cautious. Promoter ownership is stable at 57.49%. The divergence — FII nibbling, DII trimming — suggests the institutional view is split: foreigners see valuation opportunity in a CDMO turnaround, while domestic investors remain skeptical of execution.
1 · Q2 FY27 revenue and EBITDA
Management guided Q2 'significantly better' than Q1. ADC payload delivery and Phase 3 KSM commercial supply orders expected. Watch whether sequential revenue improvement validates Phase 3 pipeline thesis or if delays push delivery into Q3.
2 · Restocking molecule phased delivery progress
First destocking molecule spread over 2 years (Q4 FY27 → FY28). Second molecule timing expected by Q2 call. Monitor whether both molecules materialize as expected or slip further into FY28.
3 · NJ Bio utilization and cost-to-revenue alignment
Management prioritizing revenue growth and FTE renewal to offset biotech funding headwinds. Watch quarterly EBITDA: if NJ Bio remains below -₹300 Cr EBITDA in Q2, consolidation drag will persist into H2 despite revenue mix improvement.
4 · December 2026 guidance reset
CEO Umang promised clarification on ₹1B FY30 target, 3–4 year segment growth ranges, and margin recovery path. This is the credibility test: either management quantifies targets (gaining confidence) or defers again (losing credibility).
5 · Specialty Chemicals and AgChem qualification ramp
Specialty Chemicals declined 34.7% YoY, with AgChem skewed to H2. FY27 positioned as 'year of qualification'. Watch whether FY27 new product launches and one active ingredient registration progress as planned, setting up FY28 margin recovery.
Cohance delivered the warned revenue trough (₹4,223 Cr, down 23% YoY) but with a profitability collapse (PAT -₹45.2 Cr) driven by NJ Bio consolidation (₹328 Cr EBITDA loss). The gap between guided revenue miss (expected) and profit miss (not telegraphed) is the story of the quarter. Standalone business at 9.2% EBITDA margin is operationally sound; Sapala at 2.5x growth is a genuine bright spot. But NJ Bio's 94% negative margin and biotech funding headwinds make near-term consolidated profitability recovery dependent on Phase 3 conversions (assumed >50% approval), restocking over 2 years (slower than needed), and Sapala scaling (underway).
Management's H2 FY27 recovery thesis is material but unproven; the vagueness on margin recovery magnitude and the downgrade of ₹1B FY30 to 'aspiration' signal incomplete planning. The 50% drawdown from all-time high now sits near technical support; the bounce on day 1–5 after result (held at +4.59%) suggests the market believes the recovery narrative. But until Phase 3 conversions materialize and NJ Bio shows a credible path to profitability, execution risk remains high.
The number to track: consolidated EBITDA margin in Q2 and H2. If it begins recovery (moving toward 5%+ by Q3), the Phase 3 thesis is working and NJ Bio is scaling revenue. If it stays <3%, consolidation drag persists and holders are betting on a 3–4 year CDMO turnaround with no near-term margin visibility. Until then, this is a hold.
New CEO's First Print: Can Umang Vohra Stabilize API Plus While Scaling Specialty?
Cohance reports Q1 FY-2027 results on August 5 with a new executive at the helm. After a 54% slide from ATH, the Street stays constructive (6 buy, ₹525 GS target), betting on management's CDMO execution playbook. Watch for API Plus recovery and margin trajectory under Vohra's operational discipline.
The Setup
Cohance reports Q1 FY2027 results on August 5, 2026 — the first print under new Executive Chairman and Group CEO Umang Vohra (ex-Cipla), who took charge in May 2026. The leadership reset follows a sharp 54% decline from the stock's all-time high of ₹917.50, yet analyst consensus leans constructive: 6 buy ratings, zero sell, with Goldman Sachs maintaining a Buy and reiterating a ₹525 target (24% upside from ₹422 current). The Street's confidence hinges on Vohra's track record scaling Cipla's commercial and operational platform — now tasked with stabilizing the API Plus business (down 8% YoY in FY2026) while sustaining the Specialty Chemicals momentum (+32% YoY). This quarter is less about beating numbers and more about signaling whether the new regime can restore execution credibility.
~₹350–360 Cr
Growth of 25–28% YoY in line with analyst consensus of 25.5% revenue CAGR
~24–26%
Historical range; new CEO focus on CDMO scale discipline may inflate or flatten vs prior quarters
TBD stabilization
Regulatory headwinds -8% YoY last year; Q1 trend is the real test of recovery trajectory
~32% YoY growth
Bright spot; oligonucleotides and ADC ramp expected to sustain momentum into FY27
A strong quarter would show API Plus stabilizing (flat or low-single-digit growth) with margins held, Specialty Chemicals sustaining +28–35% growth, and Vohra signaling capital discipline amid the $285M promoter borrowing (share pledge disclosed June 2026). A weak quarter would indicate continued API headwinds (double-digit declines), margin compression from mix shift, or silence on FY27 execution roadmap — each eroding the new-CEO-led recovery narrative.
On Track?
FY2026 closed with Specialty Chemicals proving the growth engine — the API Plus regulatory drag (tariff/capacity constraints) was depth, not breadth. Analysts forecast 25.5% revenue and 38.9% earnings CAGR for Cohance; Q1 FY27 sets the tone for whether that reset (new management, diversification, CDMO focus) can deliver. Vohra's Cipla pedigree signals operational tightening and customer intimacy; the Street's constructive stance reflects betting his playbook works. If Q1 shows API stabilization + Specialty momentum + clearer guidance on CDMO scale (e.g., new capacity timelines, customer wins), consensus holds. If API continues to bleed and margins slide, the 54% drawdown from ATH may prove prescient, and the ₹525 target recalibrates sharply.
What the Street Says
Since Last Quarter
1 · Leadership Reset (April–May 2026)
Vivek Sharma resigned as Executive Chairman (April 30); Umang Vohra appointed Executive Chairman (May 1) and Group CEO (May 20, effective). Vohra brings 30+ years of pharma leadership, most recently Cipla CEO. CFO Himanshu Agarwal resigned June 17 (pursuing new role). Transitions managed with Sharma advisory overlap (9 months) to smooth execution continuity.
2 · Promoter Pledge for $285M Facility (June 18–19)
Promoters (Berhyanda Limited, Jusmiral Holdings) pledged 57.49% of shares as security for a $285M loan. Encumbrance subsequently released on same date, per CSC Global Capital Markets (Singapore) disclosure. Signal: refinancing activity amid growth capex plans, though the pledge–release timing suggests tactical liquidity management rather than distress.
3 · ESOP Approvals (July 23)
Board approved in-principle ESOP grants and share allotments for senior staff, signaling commitment to talent retention under new CEO. Routine governance, but timing aligns with Vohra's on-boarding — retention focus as he reshapes the operating culture.
4 · FY2026 Audited Results Approved (May 12)
Board approved audited FY2026 results (full-year and Q4). No material surprises flagged; governance on schedule.
Three Things to Watch on August 5
1 · API Plus Trajectory
Is the -8% YoY headwind from FY2026 stabilizing, or accelerating? A flat-to-low-single-digit decline signals containment; double-digit falls re-ignite execution doubts. Vohra's commentary on capacity expansion, customer wins, and tariff/regulatory roadmap will matter as much as the number.
2 · Specialty Chemicals Sustenance
Can +32% YoY growth persist into Q1, or is it cooling? Oligonucleotides and ADC ramp are the narrative — if Q1 shows a sharp deceleration, the growth story stalls. Management commentary on new customer additions and capacity utilization will clarify.
3 · FY2027 Guidance & Capital Allocation
Vohra's first public roadmap — revenue/EBITDA guidance, capex plans, CDMO scale targets, and how he'll deploy the $285M promoter facility proceeds. This is the make-or-break moment for market confidence in the reset. Vague or cautious guidance prolongs the valuation discount; bold but credible targets re-engage the bull thesis.
Cohance's Q1 FY2027 result is less a financial proof point than a management credibility checkpoint. With a new CEO embedded for just 2.5 months, the Street is banking on Umang Vohra's operational playbook to crack the API Plus nut and accelerate CDMO scaling — the beating heart of the 25.5% revenue / 38.9% earnings growth consensus. The 54% drawdown from ATH has priced in execution risk; a steady quarter with clear FY27 roadmap could re-engage the bull case. Watch API stabilization, Specialty momentum, and Vohra's capital discipline signal.
Guided miss: execution on plan, but NJ Bio drag and vague recovery timeline crimp credibility
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade B
Met Q1 lowest-quarter guidance. But PAT miss is severe; NJ Bio drag unbudgeted. $1B FY30 target downgraded to aspiration.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Cohance delivered the warned Q1 trough correctly (revenue -23% YoY as guided), but profitability collapse (PAT loss ₹45 Cr, -197% YoY) is deeper than revenue decline and heavily driven by NJ Bio consolidation (-₹328 Cr EBITDA on ₹350 Cr sales). Management's H2 recovery thesis hinges on Phase 3 conversions (10 molecules, >50% approval hoped), restocking over 2 years, and Sapala scaling—all material but unproven. The core risk: NJ Bio and small molecule CDMO differentiation remain unresolved; margin recovery to 30%+ is vague on timing and magnitude.
₹422.3 Cr
Revenue · −23.1% YoY₹-45.2 Cr
Reported PAT · −197.4% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Q1 lowest quarter ever as guided
METRevenue ₹422.3 Cr (-23.1% YoY), as warned, matching prior call guidance
Sapala 2.5x growth in oligonucleotides
METSapala added ₹274 Cr revenue at 2.5x YoY, maintained strong EBITDA margin
NJ Bio losses temporary, managed for revenue growth
OVERSTATEDNJ Bio ₹350 Cr revenue with -₹328 Cr EBITDA loss (-94% margin), not improving; biotech funding concerns cited
Restocking order secured for destocked molecule
PartialOne molecule restocking order "spread over 2 years" Q4 FY27 → FY28; second destocking molecule timing uncertain
Pharma CDMO to see strong improvement Q2+ driven by conversions
Partial10 Phase 3 molecules in pipeline, but "some may not get approval"; recent deliveries bimodal (fresh + maturing); realistic >50% approval rate
Standalone 9.2% EBITDA margin sustainable
OVERSTATEDStandalone (₹3,599 Cr) at 9.2% margin vs 30%+ historical; largely because high-margin CDMO declined 38.7%, low-margin specialty chem fell 34.7%
Earnings quality
What changed since the last call
NJ Bio consolidation now mandatory
DowngradePost-acquisition full consolidation of loss-making NJ Bio (₹350 Cr revenue, -₹328 Cr EBITDA) pulls consolidated margin from 9.2% (standalone) to 2.2%. Not explicitly called out as new drag.
$1B FY30 revenue target
WithdrawnUmang explicitly calls it "aspiration", says "may be a little bit away from it over the next 3-4 years", defers granularity to December. Effectively downgraded from committed target.
ADC/oligonucleotide long-term guide
UpgradeSapala 2.5x growth Q1; oligonucleotide shipments under orphan drug program commenced; amidites facility commercialization planned. Umang sees 3–4 year doubling potential, not quantified.
H2 FY27 recovery confidence
NeutralReaffirmed prior guidance that H2 will show growth vs H1; supported by restocking + Phase 3 conversions + utilization recovery. Still on track vs prior call.
The Q&A
Analysts pressed hard on: small molecule CDMO differentiation vs peers, $1B FY30 credibility, margin recovery path and magnitude, NJ Bio cost fix timing. Management held firm on relationship depth + science moat + cost discipline, but offered no hard timeline for profitability. Umang defensive on vagueness; CFO Himanshu cautious on margin recovery ('closer to previous year' by FY28, then accelerate). Q&A tone: skeptical but respectful.
3-4 year growth outlook per segment — Kunal Dhamesha, Macquarie
PartialCDMO (small molecule + ADCs + oligonucleotides) expected doubling in 3–4 years. API+ CAGR business, 30–40% of potential. AgChem/Spec Chem improving but early stage. No quantified FY27 guidance; H2 improvement expected.
Small molecule CDMO differentiation — Bansi Desai, JP Morgan
PartialThree-legged: (1) anchor customer relationships built over 7–10 years, (2) science envelope + analytical methods deepened by tech transfer, (3) cost in niche chemistry (not race-to-bottom). Peers moved faster; we catching up via widening existing relationships.
Phase 3 pipeline confidence — Bansi Desai, JP Morgan
AnsweredYes, >50% approval rate expected; bimodal portfolio (fresh + maturing) explains recent revenue decline, supports future growth. Positioned well with customers already.
Margin recovery path — Shyam Srinivasan, Goldman Sachs
PartialUmang: 3–4 year outlook suggests strong recovery. Himanshu: expect margins closer to 'previous year %' by end FY27, accelerate FY28 onwards. Difficult to articulate exact level now; operating leverage will drive recovery as revenue grows.
$1B FY30 revenue target — Foram Parekh, BOB Capital Markets
DodgedUmang: No granularity yet. Target now feels like an aspiration. May be 'a little bit away' over next 3–4 years. Will clarify by December.
Restocking molecule recovery — Foram Parekh, BOB Capital Markets
PartialOne molecule secured, but order spread over 2 years. Second molecule progress awaited. Too early to quantify FY27 contribution. Clarity expected by Q2 call.
API+ margin profile — Foram Parekh, BOB Capital Markets
PartialGunjan: Yes, differentiated portfolio (CNS focus, control substances, innovator relationships). Margin profile "handsome", top tier in generic API space. Sustained growth via new product filings (7 in FY27, 9 last year). No exact %.
NJ Bio cost fix and timeline — Kunal Dhamesha, Macquarie
AnsweredUmang: NJ Bio is a prime target. Lost biotech FTE customers due to funding concerns. Goal: match cost with revenue generation. Not yet cutting; first optimizing for utilization. Near-term NJ Bio expected to continue weighing on consolidated performance.
Guidance
H2 FY27 return to YoY growth (vs H1 decline)
MediumSupported by restocking orders, Phase 3 conversions (10 molecules, >50% approval hoped), Sapala scaling, utilization improvement. But timing of Phase 3 revenue is uncertain.
Sequential improvement Q2 FY27 vs Q1
HighQ2FY27 expected "significantly better" than Q1; deliveries moved from Q1 now on track for Q2/Q3. Restocking and commercial OTIF support near-term revenue.
EBITDA margin recovery weighted to H2 FY27
MediumGiven unusually low operating base in Q1, margin recovery will depend on revenue conversion, business mix, utilization. Management cautious on magnitude and timing.
Standalone margin closer to prior year % by FY27 end, accelerate FY28
LowStandalone 9.2% in Q1 vs 30%+ historical; CFO Himanshu non-specific on recovery path. No guidance on when consolidated margins recover to 20%+.
~₹3 billion FY27 capex (prior guidance maintained)
HighFocused on ADC, oligonucleotide, API+, specialty chemicals. Q1 capex ₹598 Cr; pace expected to continue. Strategic areas: amidites, ADC linkers, flow reactors.
Risks the call surfaced
NJ Bio profitability
HighNJ Bio -₹328 Cr EBITDA on ₹350 Cr revenue (94% negative margin). Biotech funding concerns caused FTE customer loss. Management committed to cost-to-revenue alignment but timeline unclear.
Phase 3 molecule conversion
High10 Phase 3 molecules in pipeline; management assumes >50% approval rate to feed future growth. But clinical failures, regulatory delays, or customer delays (not in hurry to switch suppliers) could derail timeline.
Restocking molecule realization
MediumPrior ₹260 Cr destocking impact. One molecule restocking order secured but spread over 2 years (Q4 FY27 → FY28). Second molecule progress unknown. Limits near-term revenue recovery.
Small molecule CDMO competition
MediumIntense competition; Umang claims moat is relationships (7–10 years to build), science envelope, niche chemistry. But peers (Divi's, Laurus) are larger and more established. Cohance is in early catch-up phase.
Margin recovery timeline vagueness
MediumManagement defers granularity on EBITDA margin recovery to H2/FY28. Standalone 9.2% in Q1 vs 30%+ historical; consolidated 2.2%. No clear path to 20%+ consolidated or when $1B revenue + historical margin combo materializes.
$1B FY30 revenue target
MediumPrior ₹1B (approx $12B USD equivalent) FY30 revenue target now downgraded to "aspiration." Umang admits "may be a little bit away" and defers details to December. Signals management overcommitted or underestimated execution risk.
Management
Score 6/10. Umang (new CEO, 3–4 months in) candid on challenges but vague on solutions. Defers quantified guidance to December. CFO Himanshu clear on financials but cautious on recovery timing. Team avoids over-assertion but also lacks crisp commitments. Transparency on NJ Bio drag is good; vagueness on margin recovery is not. Met Q1 guided low-point (revenue -23% YoY as expected). Operational OTIF 100%; customer audits pass. But PAT collapse (-197% YoY) and NJ Bio -₹328 Cr EBITDA are execution shortfalls not fully anticipated. Restocking realization phased over 2 years (slower than hoped).
1 · Q2 FY27
ADC payload delivery and Phase 3 KSM commercial supply orders expected
2 · Q4 FY27 → FY28
Destocked molecule restocking order phased delivery (2-year spread)
3 · H2 FY27
Return to YoY revenue growth driven by CDMO Phase 3 commercializations and Sapala scaling
The core risk: NJ Bio and small molecule CDMO differentiation remain unresolved; margin recovery to 30%+ is vague on timing and magnitude.